1 Cost-effectiveness of testing for *Mycoplasma genitalium* among men who have sex with

2 men in Australia

- 3
- 4 Jason J. Ong^{1,2,3}, Aaron G. Lim⁴, Catriona S. Bradshaw¹, David Taylor-Robinson⁵, Magnus
- 5 Unemo^{6,7}, Patrick J. Horner⁴, Peter Vickerman⁴, Lei Zhang^{1,3,8}
- 6
- 7 1. Central Clinical School, Monash University, Melbourne 3004, Australia
- 8 2. Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical
- 9 Medicine, London WC1E 7HT, United Kingdom
- 10 3. China-Australia Joint Research Center for Infectious Diseases, School of Public Health,
- 11 Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China.
- 12 4. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8
- 13 1TH, United Kingdom
- 14 5. Faculty of Medicine, Imperial College London, London SW7 2BX, United Kingdom
- 15 6. WHO Collaborating Centre for Gonorrhoea and other STIs, Örebro University, Örebro 702
- 16 81, Sweden
- 17 7. Institute for Global Health, University College London, London WC1E 6BT, United
- 18 Kingdom
- 19 8. Artificial Intelligence and Modelling in Epidemiology Program, Melbourne Sexual Health
- 20 Centre, Alfred Health, Melbourne 3053, Australia
- 21

22 CORRESPONDING AUTHOR:

- 23 Jason J. Ong
- 24 580 Swanston Street
- 25 Carlton, Victoria 3053, Australia

- 26 Phone: +613 9341 6200
- 27 Email: Jason.Ong@monash.edu
- 28
- 29 Running title: Cost-effectiveness of testing for MG
- 30 Word count: Abstract (236), Main text (2285)
- 31
- 32

33 KEY MESSAGES

34	• What is already known on this topic - Mycoplasma genitalium (MG) is a sexually
35	transmitted pathogen with rising antimicrobial resistance.
36	• What this study adds - This economic evaluation found that testing only
37	symptomatic men who have sex with men (MSM) is the most cost-effective option.
38	When the costs per antibiotic consumed is greater than \$150, any testing for MG is no
39	longer cost-effective.
40	• How this study might affect research, practice or policy - Among testing strategies
41	for MSM, testing for MG should be restricted to symptomatic men only.
42	
43	ABSTRACT
44	Objectives
45	Mycoplasma genitalium (MG) disproportionately affects men who have sex with men (MSM).
46	We determined the cost-effectiveness of testing strategies for MG using a healthcare provider
47	perspective.
48	Methods
49	We used inputs from a dynamic transmission model of MG among MSM living in Australia
50	in a decision tree model to evaluate the impact of four testing scenarios on MG incidence: 1)
51	no one tested; 2) symptomatic MSM; 3) symptomatic and high-risk asymptomatic MSM; 4)
52	all MSM. We calculated the incremental cost-effectiveness ratios (ICERs) using a willingness
53	to pay threshold of \$30,000 AUD per QALY gained. We explored the impact of adding an
54	AMR tax (i.e. additional cost per antibiotic consumed) to identify the threshold whereby any
55	testing for MG is no longer cost-effective.
56	Results

57 Testing only symptomatic MSM is the most cost-effective (ICER \$3,677 per QALY gained)

58 approach. Offering testing to all men is dominated (i.e. not recommended because of higher

- 59 costs and lower QALYs gained compared to other strategies). When the AMR tax was above
- 60 \$150, any testing for MG was no longer cost-effective.

61 Conclusion

- 62 Testing only symptomatic MSM is the most cost-effective option even when the potential
- 63 costs associated with AMR are accounted for (up to \$150 additional cost per antibiotic
- 64 consumed). For pathogens like MG where there are anticipated future costs related to AMR,
- 65 we recommend models to test the impact of incorporating these costs as they can change the
- 66 conclusions of cost-effectiveness studies.
- 67
- 68 Keywords: Mycoplasma genitalium, sexually transmitted infection, economic evaluation,
- 69 antimicrobial resistance, screening
- 70

71 **INTRODUCTION**

Mycoplasma genitalium (MG) is a sexually transmitted bacterium that can cause urethritis,
cervicitis, endometritis, and pelvic inflammatory disease.¹ A recent systematic review
estimates that MG prevalence is 1.3% (95% CI: 1.0-1.8) among the asymptomatic general
population in countries with higher Human Development Index (HDI) levels and 3.9% (95%
CI: 2.2-6.7) in countries with lower HDI levels.² Of concern, there is a high and rising
prevalence of antimicrobial resistance (AMR) in MG globally.³

78

Studies in men who have sex with men (MSM) have reported a higher prevalence of MG compared to the general population. For example, in a study of 1001 asymptomatic MSM attending a sexual health clinic in Australia, a prevalence of 9.5% was reported.⁴ However, although MG may cause urethritis and proctitis in MSM,^{1,5} there are no reproductive sequelae as in women.⁶ Consequently, besides treating MG in MSM to alleviate symptoms, there is uncertainty over the benefits of testing for MG in achieving population-level control among MSM.

86

87 Testing asymptomatic individuals for MG is not recommended in the Australian, European,
88 British and US MG management guidelines.⁷⁻¹⁰ This recommendation is currently based on
89 expert opinion. There is a lack of evidence regarding the benefits of testing and treating for
90 MG among asymptomatic individuals, and no cost-effectiveness analysis has been published.

91

In this study, we aim to determine the cost-effectiveness of testing for MG using a healthcare provider perspective among MSM living in Australia. We evaluated the cost-effectiveness of testing: 1) no one; 2) only symptomatic MSM (current recommendation); 3) symptomatic and high-risk asymptomatic MSM; 4) all MSM. To account for the potential economic impact of

96 future antimicrobial resistant MG, we also imposed an AMR tax to explore whether this 97 would alter the cost-effectiveness of testing strategies. As the future cost of AMR is complex 98 and uncertain, it is challenging to monetize the direct and indirect consequences of AMR, let alone the costs for developing new antibiotics.¹¹ So, we adopted the approach used by the 99 100 World Health Organization in the 2021 Guidelines for the management of symptomatic 101 sexually transmitted infections, in their development of the vaginal discharge management 102 algorithm.¹² The AMR tax is applied at the point of antibiotic use, and is a way to incorporate 103 the detrimental effects of AMR into the net present value of the interventions under 104 consideration.¹³

105

106 **METHODS**

107 *Costs*

108 A micro-costing approach was used to identify costs from an Australian healthcare provider 109 perspective for testing and managing MG. The direct medical economic costs of testing and 110 management were collated from the Australian Pharmaceutical Benefits Scheme and data 111 from Melbourne Sexual Health Centre (MSHC), the largest publicly funded sexual health 112 centre in Australia. We accounted for costs related to the medical consultation, tests and 113 antibiotics used. The type of antibiotics used to manage MG infection was based on the current management guidelines at MSHC (Table 1) and the European guidelines¹⁰ (as part of 114 115 our sensitivity analysis). All costs are reported in Australian dollars (2021 AUD). A gamma 116 distribution was used to characterise the uncertainty for costs (based on +/- 30% of the base-117 case estimate) in the probabilistic sensitivity analysis.

118

The initial cost of testing includes one consultation and one test. If an individual tests positivefor MG, he will incur extra costs related to two additional consultations: one consultation for

121 receiving treatment, and one consultation for the test of cure. The antibiotics prescribed will 122 depend on whether the MG strain is macrolide-susceptible or -resistant (Table 2). We 123 evaluated how adding an AMR tax (ranging from 0 to \$200) would affect the cost-124 effectiveness of testing strategies. There is no single willingness to pay (WTP) threshold in 125 Australia, although there is evidence that medicines are more likely to be recommended for listing with an ICER around \$30,000 than above \$70,000.¹⁴ We used the more conservative 126 127 WTP of \$30,000 per QALY gained in the analysis, but also provide the probability of being 128 cost-effective across a range of WTP in the cost-effectiveness acceptability curves.

129

130 Model

131 We created a decision tree model in TreeAgePro 2021 (TreeAge Software, Williamstown, 132 MA, USA) for four testing scenarios: 1) no one tested; 2) only symptomatic MSM tested (the 133 current recommendation); 3) symptomatic and high-risk asymptomatic MSM tested; 4) all 134 MSM tested. We defined high-risk men as those who reported more than ten sexual partners in the last six months.¹⁵ Figure 1 presents the structure of one testing scenario, which is 135 136 applied to all four scenarios in the final model. We used this decision tree model to calculate 137 the total cost, total QALYs gained and incremental cost-effectiveness ratio for the four testing 138 scenarios using estimates from a dynamic transmission model of MG among MSM living in 139 Australia that we previously developed.¹⁶ This dynamic transmission model simulated a 140 cohort of MSM who could be infected with wild-type or macrolide-resistant MG. The 141 dynamic model assumes: 1) a closed cohort of MSM (i.e. no transmission between MSM and 142 non-MSM groups, and no births or deaths were incorporated); 2) a treatment effectiveness of 92-95% using resistance-guided therapy;¹⁷ 3) no transitions between low- and high-risk men, 143 144 but sexual mixing can occur between the two populations; 4) the transmission rate is

independent of symptom status and the type of MG strain; and 5) 77% of those diagnosed
would receive treatment.⁵

147

148 Model inputs

149 There are limited data for utility weights related to MG (eTable 1). For men with 150 complications (defined as ongoing symptoms and anxiety associated with the infection), we 151 assumed a utility weight of 0.96, which was based on 3 months with disutility weight of 0.16 152 (based on urethritis).¹⁸ For men receiving a positive MG test with a resistant strain, we 153 assumed 100% had a disutility weight of 0.1 for the first month, 10% with disutility weight of 154 0.1 in the second month, and 2% with disutility weight of 0.1 in the third month. These 155 proportions were based on the clinical experience of sexual health clinicians at MSHC. For 156 men receiving a positive MG test with a wild-type strain, we assumed 100% had a disutility 157 weight of 0.05 for the first month. The probabilities of men having more than 10 partners in 158 the last 6 months, proportion with ongoing symptoms, and proportion of men screened based 159 on symptoms were derived from unpublished data from MSHC.

160

161 *Sensitivity analyses*

To examine the impact of parameter uncertainty (eTable 2), we conducted one-way and probabilistic sensitivity analyses and present these as tornado plots and cost-effectiveness acceptability curves, respectively. A Monte Carlo simulation with 100,000 samples was run for the probabilistic sensitivity analysis. In secondary analyses, we tested the effect of a range of AMR tax (\$20 to \$200) on the cost-effectiveness acceptability curves, and to identify the threshold level of the AMR tax where any testing for MG is no longer cost-effective. We also explored a scenario whereby MG testing is conducted in three anatomical sites (eTable 3).

- 170 We report our findings using the Consolidated Health Economic Evaluation Reporting
- 171 Standards 2022 (CHEERS 2022, Appendix).
- 172

173 **RESULTS**

174 <u>Primary cost-effectiveness analysis</u>

Table 3 summarizes the total and incremental cost and QALYs gained in a population of 10,000 MSM. It shows that testing all men will always be dominated (i.e. not recommended because of high costs and lower QALYs gained compared to other strategies) regardless of the range of the AMR tax. Testing symptomatic MSM is cost-effective (ICER \$3,677 per QALY gained) compared to no testing. eFigure 1 summarizes the results from the probabilistic sensitivity analyses, demonstrating the probability of being cost-effective at the WTP threshold of \$30,000 was 40.7% for testing symptomatic MSM only.

182

183 Secondary cost-effectiveness analyses: implementing an AMR tax

eFigures 2 to 6 demonstrates the impact of increasing the AMR tax from \$20 to \$200. The
strategy of not testing anyone becomes most cost-effective when the AMR tax is more than
\$150.

187

188 Sensitivity analyses

The univariate sensitivity analysis results are shown in eFigures 7 to 9. The ICER for testing only symptomatic men (current recommendation) compared with no testing was most influenced by the probability of resistant MG in low-risk MSM, the AMR tax and disutility of MG complications. However, the ICERs remain below the willingness to pay threshold, suggesting that testing only symptomatic MSM is cost-effective compared to no testing. The ICER for testing only symptomatic men compared with testing both high-risk asymptomatic

men and symptomatic men was most influenced by AMR tax, the probability of wild-type MG in high-risk MSM and probability of wild-type MG. The ICER for testing only symptomatic men compared with testing all MSM was most influenced by the probability of resistant MG in low-risk MSM, the disutility of resistant MG and the AMR tax. However, all ICERs remain cost-saving, suggesting that testing only symptomatic MSM will always be cost-saving compared to testing all MSM. Testing three anatomical sites would increase total costs for each scenario but does not change our conclusions (eTable 3).

202

203 DISCUSSION

With increasing access to nucleic acid amplification tests for MG, it is important to ensure recommendations to test for MG are informed by robust evidence, including economic evaluations. Thus, our cost-effectiveness analysis provides evidence for the value in money for various testing strategies for an infection that is predominantly asymptomatic in MSM¹⁹, but has rising AMR.^{3,20} Our findings strengthen the evidence base for the current international and national guidelines that recommend testing in symptomatic individuals only.^{7,8,21}

211

212 The current recommendation to test for MG among symptomatic individuals with specific 213 indications is an example of antibiotic stewardship. Overuse of antibiotics has been linked to 214 rising resistance in many pathogens²² and specifically for MG, countries with a higher 215 background of macrolide use has been associated with higher prevalence of macrolideresistant MG.^{23,24} Thus, restricting antibiotics only for symptomatic MSM minimizes 216 217 antibiotic consumption in a population that already receives far more antibiotics than the 218 general population.²⁵ Screening asymptomatic men for MSM is problematic on a number of 219 levels. There are no data to suggest asymptomatic MG in MSM is posing a significant risk to

health and, due to rising AMR, management of MG is becoming increasingly complex and costly, with challenges in accessing second- or third-line antibiotics outside of specialist sexual health services. Further, we need to consider the harms associated with screening asymptomatic MSM, including the psychological morbidity of being diagnosed with an asymptomatic infection that is unlikely to cause complications among MSM but is increasingly hard to cure and subjects individuals to repeated and often long courses of antibiotics.

227

228 There are increasing reports of the rapid spread of macrolide-resistant MG and the emergence of fluoroquinolone resistance globally.³ Where suboptimal treatment regimens are prescribed 229 230 (particularly in the context of rising macrolide resistance), offering MG testing might lead to increases in macrolide-resistant MG.¹⁶ This phenomenon is also observed for malaria²⁶ and 231 tuberculosis.²⁷ Subtherapeutic or subinhibitory antibiotic concentrations can promote the 232 233 development of AMR in not only the target organism but also in other pathogens and 234 commensals.²⁸ Consistent with this, in settings with greater use of macrolides, there is a higher prevalence of macrolide-resistant MG.²⁹ This stresses the urgency of implementing 235 236 resistance-guided therapy for MG to ensure that the most appropriate antibiotic is selected for eliminating the pathogen.¹⁷ 237

238

Since the advent of antibiotics, we have observed that the effectiveness of antibiotics generally wanes over time against most pathogens, particularly when there is overconsumption. Thus, economic models should account for costs related to the development and spread of AMR.^{30,31} Currently, very few models explicitly account for the future costs of AMR.³² Most studies include direct health costs but do not consider non-health perspectives (e.g. societal impact).³² There remains no consensus of how best to capture these costs.

245 Importantly, future costs should also include treating sequelae that arise from untreatable 246 infections (including prolonged hospitalization), the need to use increasingly toxic and costly 247 antibiotics, and the development of new antibiotics to combat infection. While it may not be 248 feasible to accurately capture these specific cost items, the strength of our approach to use an 249 AMR tax would incorporate these components to explicitly demonstrate the impact of AMR 250 on present decision-making. However, a limitation is that we could not disaggregate the 251 direct and indirect costs associated with AMR, nor account for the unmeasured impact on 252 other bacteria and the microbiome in the setting of antibiotic overconsumption.

253

254 The strength of our study is the use of inputs from a dynamic transmission model for MG to 255 evaluate the cost-effectiveness of a variety of testing strategies for MSM. Given the 256 importance of AMR for MG, we also explored the impact of incorporating potential costs of 257 AMR in our models. Our study should be read in light of some limitations. First, our model 258 calculates the incidence at equilibrium with inputs from the transmission dynamic model; 259 thus, we do not have data on how quickly equilibrium is reached. Second, our findings are 260 specifically for MSM and not for heterosexual populations. The disutility from reproductive 261 morbidity associated with MG will need to be accounted for in future studies in heterosexual 262 populations. Third, the AMR profile of MG varies markedly depending on the country and 263 population,³ so we recommend context-specific economic evaluations that also account for 264 locally-derived health and AMR costs. Fourth, there is no consensus on an acceptable 265 threshold for an AMR tax, but we recommend that future models incorporate this as part of 266 their sensitivity analyses given AMR's significant impact on both cost and effectiveness.³³ 267 Last, due to absence of data, several model inputs were based on assumptions. Our univariate 268 sensitivity analyses highlight the parameters that would most likely change the ICER of the 269 testing strategy, and thus would benefit from more accurate measurements in future models.

2	7	Δ
L	1	υ

271	In conclusion, our study confirms that the current recommendation for MG testing, i.e. testing
272	only symptomatic MSM, is the most cost-effective option in an Australian context. This
273	conclusion remains robust despite uncertainties in multiple parameters, including accounting
274	for future costs of AMR.
275	
276	
277	FUNDING
278	This work was supported by the Australian National Health and Medical Research Council
279	Emerging Leader Fellowship (GNT1193955).
280	
281	COMPETING INTERESTS
282	All authors declare no conflict of interests.
283	
284	CONTRIBUTORSHIP
285	JO, LZ conceived the research idea. JO, AGL, PV and LZ constructed the dynamic
286	transmission model and conducted the economic evaluation. JO drafted the first manuscript.
287	All authors contributed to the writing of the paper and approve the final version.
288	
289	PATIENT AND PUBLIC INVOLVEMENT
290	Patients or the public were not involved in the design, or conduct, or reporting, or
291	dissemination plans of our research.
292	
293	DATA AVAILABILITY
294	All data produced in the present work are contained in the manuscript.

295

296 **REFERENCES**

- 297 1. Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from Chrysalis to 298 multicolored butterfly. Clin Microbiol Rev. 2011;24(3):498-514. 299 2. Baumann L, Cina M, Egli-Gany D, et al. Prevalence of Mycoplasma genitalium in 300 different population groups: systematic review and meta-analysis. Sex Transm Infect. 301 2018;94(4):255-262. 302 3. Machalek DA, Tao Y, Shilling H, et al. Prevalence of mutations associated with 303 resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a 304 systematic review and meta-analysis. Lancet Infect Dis. 2020;20(11):1302-1314. 305 4. Read TRH, Murray GL, Danielewski JA, et al. Symptoms, Sites, and Significance of 306 Mycoplasma genitalium in Men Who Have Sex with Men. Emerg Infect Dis. 307 2019;25(4):719-727. 308 5. Ong JJ, Aung E, Read TRH, et al. Clinical Characteristics of Anorectal Mycoplasma 309 genitalium Infection and Microbial Cure in Men Who Have Sex With Men. Sex 310 Transm Dis. 2018;45(8):522-526. 311 6. Wiesenfeld HC, Manhart LE. Mycoplasma genitalium in Women: Current 312 Knowledge and Research Priorities for This Recently Emerged Pathogen. J Infect Dis. 313 2017;216(suppl_2):S389-S395. 314 7. Soni S, Horner P, Rayment M, et al. British Association for Sexual Health and HIV 315 national guideline for the management of infection with Mycoplasma genitalium 316 (2018). Int J STD AIDS. 2019;30(10):938-950. 317 8. Australian sexually transmitted infections management guidelines for use in primary 318 care. The Australian Government Department of Health. 319 http://www.sti.guidelines.org.au/. Accessed 21st April 2017. 320 9. US Centers for Disease Control and Prevention. Sexually Transmitted Infections 321 Treatment Guidelines, 2021. Mycoplasma genitalium. 322 https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm. Accessed 323 23rd November 2021. 324 10. Jensen JS, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M. 2021 European 325 guideline on the management of Mycoplasma genitalium infections. J Eur Acad 326 Dermatol Venereol. 2022. 327 11. Naylor NR, Atun R, Zhu N, et al. Estimating the burden of antimicrobial resistance: a 328 systematic literature review. Antimicrob Resist Infect Control. 2018;7:58. 329 12. World Health Organization. Guidelines for the management of sexually transmitted 330 infections. 331 https://www.who.int/hiv/topics/vct/sw toolkit/guidelines management sti.pdf?ua=1. 332 Accessed 13th Feb 2021. 333 13. Shrestha P, Cooper BS, Coast J, et al. Enumerating the economic cost of antimicrobial 334 resistance per antibiotic consumed to inform the evaluation of interventions affecting 335 their use. Antimicrob Resist Infect Control. 2018;7:98. 336 14. Australian Government Department of Health and Aged Care. The effects of statuory 337 price reductions on the listing of new medicines.
- https://www.pbs.gov.au/info/general/working-groups/amwg/amwg-interim-report attachment-
- 340 <u>a#:~:text=While%20there%20is%20no%20single,with%20an%20ICER%20above%2</u> 241 00%2470%2C000 Accessed 4th August 2022
- 341
 <u>0%2470%2C000</u>. Accessed 4th August 2022.

240	15	STILL'S Construction Astrono (STICMA) Samuel to service the discharge to still
342	15.	STI's in Gay Men Action Group (STIGMA). Sexual transmitted infection testing
343		guidelines for men who have sex with men. STI's in Gay Men Action Group
344		(STIGMA) Web site. 2014. http://stipu.nsw.gov.au/wp-
345		content/uploads/STIGMA_Testing_Guidelines_Final_v5.pdf. Published 2014.
346		Accessed 31 Dec, 2015.
347	16.	Ong JJ, Ruan L, Lim AG, et al. Impact of screening on the prevalence and incidence
348		of Mycoplasma genitalium and its macrolide resistance in men who have sex with
349		men living in Australia: A mathematical model. <i>EClinicalMedicine</i> . 2021;33:100779.
350	17.	Read TRH, Fairley CK, Murray GL, et al. Outcomes of Resistance-guided Sequential
351		Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation. <i>Clin</i>
352		Infect Dis. 2019;68(4):554-560.
353	18.	Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. <i>EMBO Mol Med.</i>
354	10.	2014;6(6):708-720.
	10	
355	19.	Couldwell DL, Jalocon D, Power M, Jeoffreys NJ, Chen SC, Lewis DA. Mycoplasma
356		genitalium: high prevalence of resistance to macrolides and frequent anorectal
357		infection in men who have sex with men in western Sydney. Sex Transm Infect.
358	• •	2018;94(6):406-410.
359	20.	Li Y, Le WJ, Li S, Cao YP, Su XH. Meta-analysis of the efficacy of moxifloxacin in
360		treating Mycoplasma genitalium infection. Int J STD AIDS. 2017;28(11):1106-1114.
361	21.	Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on Mycoplasma
362		genitalium infections. J Eur Acad Dermatol Venereol. 2016;30(10):1650-1656.
363	22.	Olesen SW, Barnett ML, MacFadden DR, et al. The distribution of antibiotic use and
364		its association with antibiotic resistance. <i>Elife</i> . 2018;7.
365	23.	Kenyon C, Manoharan-Basil SS. Macrolide consumption and resistance in
366		Mycoplasma genitalium. Lancet Infect Dis. 2020;20(11):1235-1236.
367	24.	Kenyon C, Manoharan-Basil SS, Van Dijck C. Is There a Resistance Threshold for
368		Macrolide Consumption? Positive Evidence from an Ecological Analysis of
369		Resistance Data from Streptococcus pneumoniae, Treponema pallidum, and
370		Mycoplasma genitalium. Microb Drug Resist. 2021;27(8):1079-1086.
371	25.	Kenyon C, Baetselier I, Wouters K. Screening for STIs in PrEP cohorts results in high
372	20.	levels of antimicrobial consumption. <i>Int J STD AIDS</i> . 2020;31(12):1215-1218.
373	26.	Wang J, Xu C, Liao FL, Jiang T, Krishna S, Tu Y. Suboptimal dosing triggers
374	20.	artemisinin partner drug resistance. <i>Lancet Infect Dis.</i> 2019;19(11):1167-1168.
	27	
375	27.	Kempker RR, Kipiani M, Mirtskhulava V, Tukvadze N, Magee MJ, Blumberg HM.
376		Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among
377		Patients with Multidrug-Resistant Tuberculosis. <i>Emerg Infect Dis.</i> 2015;21(6):992-
378	•	
379	28.	Viswanathan VK. Off-label abuse of antibiotics by bacteria. <i>Gut Microbes</i> .
380		2014;5(1):3-4.
381	29.	Pitt R, Unemo M, Sonnenberg P, et al. Antimicrobial resistance in Mycoplasma
382		genitalium sampled from the British general population. Sex Transm Infect.
383		2020;96(6):464-468.
384	30.	Niewiadomska AM, Jayabalasingham B, Seidman JC, et al. Population-level
385		mathematical modeling of antimicrobial resistance: a systematic review. BMC Med.
386		2019;17(1):81.
387	31.	Birkegard AC, Halasa T, Toft N, Folkesson A, Graesboll K. Send more data: a
388		systematic review of mathematical models of antimicrobial resistance. Antimicrob
389		Resist Infect Control. 2018;7:117.
390	32.	Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance:
391		how much do we really know? Clin Microbiol Infect. 2014;20(10):973-980.

392 393	33.	O'Neill J. Tackling drug resistant infections globally: final report and recommendations. <u>https://amr-</u>
394		review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf. Accessed
395		1st Feb 2019.
396	34.	Australian Government Department of Health. The Pharmaceutical Benefits Scheme.
397		https://www.pbs.gov.au/pbs/home. Accessed 20th August 2021.
398	35.	Medicare Benefits Schedule.
399		www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-
400		<u>Schedule-MBS-1</u> . Accessed 10th July 2014.
401	36.	Melbourne Sexual Health Centre. Mycoplasma genitalium treatment guidelines.
402		https://www.mshc.org.au/health-professionals/treatment-guidelines/mycoplasma-
403		genitalium-treatment-guidelines, Accessed 24th Feb 2022.

405

406 TABLES

407 Table 1 The direct health costs of managing a patient diagnosed with macrolide-resistant *Mycoplasma genitalium* using antibiotics recommended at Melbourne

408 Sexual Health Centre, and the European guidelines.

	Initial treatment (100%)	Test of cure	Failed 1 st line	Test of cure	Failed 2 nd line	Test of cure
			(10%)		(2%)	
Melbourne Sexual						
Health Centre						
Antibiotics	Doxycycline 100 mg bd 7 days (\$35.72)		Doxycycline 100 mg bd 7 days (\$35.72)		Combination Doxycycline	
	followed by		followed by		100 mg bd 10 days (\$71.44)	
	Moxifloxacin 400 mg daily for 7 days (\$86.10)		Combination Doxycycline 100 mg bd		+ Pristinamycin 1 g tds 10	
			daily (\$35.72) + Sitafloxacin 100 mg bd		days (\$182.81)	
			7 days (\$145.04)		OR	
					Minocycline 100 mg 14	
					days ¹ (\$22.53)	
Consultation	\$38.75	\$38.75	\$38.75	\$38.75	\$38.75	\$38.75
Test		\$39.65		\$39.65		\$39.65
European						
Guidelines ¹⁰						
Antibiotics	Moxifloxacin 400 mg daily for 7 days (\$86.10)		Pristinamycin 1 g four times daily for 10		Minocycline 100 mg two	
			days (\$182.81)		times daily for 14 days	

						(\$22.53)	
	Consultation	\$38.75	\$38.75	\$38.75	\$38.75	\$38.75	\$38.75
	Test		\$39.65		\$39.65		\$39.65
410							

410 ¹ Based on MSHC data, we estimate that 70% would use minocycline

411 Table 2 Cost (AUD) model input parameters

Cost parameter	Cost (\$) Gamma distribution		Reference and assumptions	
		(alpha, lambda)		
Doctor's consultation	38.75	11.1, 0.29	PBS ³⁴	
Test for MG (including test for macrolide resistance)	39.65	11.1, 0.28	$\mbox{MBS}^{35} + \$11$ for resistance test^1	
Azithromycin 1g stat then 500 mg daily for another 3	67.68	-	PBS ³⁴	
days				
Doxycycline 100 mg twice daily for 1 week	35.72	-	PBS ³⁴	
Moxifloxacin 400 mg daily for 7 days	86.10	-	MSHC ³⁶	
Pristinamycin 1g three times a day for 10 days	182.81	-	MSHC ³⁶	
Minocycline 100 mg twice daily for 14 days	22.53	-	PBS ³⁴	
Sitafloxacin 100 mg twice daily for 7 days	145.04	-	MSHC ³⁶	
Cost of antibiotics for treating wild type (MSHC) ²	103.40	11.1, 0.11	PBS ³⁴	
Cost of antibiotics for treating wild type (European	67.68	11.1, 0.16	10	
guidelines)				
Cost of antibiotics for treating resistant MG(MSHC)	147.45	11.1, 0.08	PBS ³⁴	
Cost of antibiotics for treating resistant MG ² (European	104.83	11.1, 0.11	10	
guidelines)				

412 ¹Discussion with local laboratory (September 2021)

413 ² Based on Doxycycline 100 mg bd 1 week followed by Azithromycin 1 g stat, then 500 mg daily for another 3 days

414 AUD = Australian dollars, MBS = Medicare Benefits Schedule; MG = *Mycoplasma genitalium*; MSHC = Melbourne Sexual Health Centre;

415 PBS = Pharmaceutical Benefits Scheme

417 Table 3 Cost-effectiveness of testing for *Mycoplasma genitalium* among 10,000 men who have sex with

418 men, according to various levels of AMR tax

	Cost	Incremental	QALY	Incremental	ICER
\$0 AMR tax		cost		QALY	
No one is tested	0		9,970		
Testing only symptomatic MSM (current	11,032	11,032	9,973	3	3,677
recommendation)					
Testing symptomatic and high-risk	103,495	92,463	9,975	2	46,232
asymptomatic MSM					
Testing all MSM	1,417,606	1,314,111	9,961	-14	Dominated
\$20 AMR tax					
No one is tested	0		9,970		
Testing only symptomatic MSM (current	15,939	15,939	9,973	3	5,313
recommendation)					
Testing symptomatic and high-risk	116,265	100,326	9,975	2	50,163
asymptomatic MSM					
Testing all MSM	1,463,541	1,347,276	9,961	-14	Dominated
\$50 AMR tax					
No one is tested	0		9,970		
Testing only symptomatic MSM (current	23,300	23,300	9,973	3	7,767
recommendation)					
Testing symptomatic and high-risk	135,419	112,119	9,975	2	56,060
asymptomatic MSM					
Testing all MSM	1,532,443	1,397,024	9,961	-14	Dominated


419 AMR = antimicrobial resistance; ICER = incremental cost-effectiveness ratio; MSM = men who have sex with men; QALY = quality-

420 adjusted life years

421

423 **FIGURES**

- 424 Figure 1. Decision tree model for the cost-effectiveness of testing for Mycoplasma genitalium among men
- 425 who have sex with men



- 428 p_HighRisk = probability of a men being at high-risk for *Mycoplasma genitalium* (MG)
- 429 p_HR_Resistant = probability that MG is resistant to macrolides for high-risk MSM
- 430 p_HR_WT = probability that MG is wild type for high-risk MSM
- 431 p_LR_Resistant = probability that MG is resistant to macrolides for low-risk MSM
- 432 p_LR_WT = probability that MG is wild type for low-risk MSM
- 433 p_Compl = probability of complications related to MG
- 434 # = 1 - other rates